Galectin Therapeutics Security Rating

Galectin Therapeutics (formerly known as Pro-Pharmaceuticals) is a biotechnology company focused on discovery and development. The Company aims to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on its carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in the treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies.